Ratings by Baird (Michael Ulz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/9/2025 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2025 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2025 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2025 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2024 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2024 | ORIC Pharamceuticals | ORIC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2023 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2023 | ORIC Pharamceuticals | ORIC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2023 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2023 | Jounce Therapeutics | JNCE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/3/2022 | Surface Oncology | SURF | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2022 | Jounce Therapeutics | JNCE | Downgrade | Neutral (Outperform) |
4.98 (1.88) |
-62.25% | Details | |
| 5/4/2021 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2020 | Alexion Pharmaceuticals | ALXN | Downgrade | Neutral (Outperform) |
118.87 (182.01) |
53.12% | Details | |
| 11/3/2020 | Jounce Therapeutics | JNCE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2020 | iTeos Therapeutics | ITOS | New Coverage | Outperform (N/A) |
21.59 (10.15) |
-52.99% | Details | |
| 9/23/2020 | Neoleukin Therapeutics | NLTX | New Coverage | Outperform (N/A) |
12.30 (3.49) |
-71.63% | Details | |
| 8/20/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2020 | ORIC Pharamceuticals | ORIC | New Coverage | Outperform (N/A) |
25.42 (13.71) |
-46.07% | Details | |
| 7/30/2020 | Genocea Biosciences | GNCA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/24/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/17/2020 | IGM Biosciences | IGMS | New Coverage | Outperform (N/A) |
62.00 (1.27) |
-97.95% | Details | |
| 7/14/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | Harpoon Therapeutics | HARP | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/29/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 4/16/2020 | Atreca Inc. | BCEL | New Coverage | Outperform (N/A) |
17.39 (0.09) |
-99.48% | Details | |
| 4/1/2020 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2020 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 1/31/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/9/2020 | Amicus Therapeutics | FOLD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2019 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 9/16/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 8/30/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/2/2019 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/19/2019 | Blueprint Medicines | BPMC | New Coverage | Outperform (N/A) |
96.33 (129.46) |
34.39% | Details | |
| 7/5/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 7/5/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/28/2019 | argenx SE | ARGX | New Coverage | Outperform (N/A) |
135.07 (717.80) |
431.43% | Details | |
| 6/19/2019 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 6/3/2019 | Genocea Biosciences | GNCA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/26/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2019 | Harpoon Therapeutics | HARP | New Coverage | Outperform (N/A) |
13.03 (23.01) |
76.59% | Details | |
| 4/22/2019 | Amicus Therapeutics | FOLD | Maintain | Outperform (N/A) |
|
Details | ||
| 4/10/2019 | Coherus Biosciences | CHRS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/2/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2019 | Proteon Therapeutics | PRTO | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2019 | NewLink Genetics | NLNK | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2019 | Karyopharm Therapeutics | KPTI | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2019 | Constellation Pharmaceuticals | CNST | New Coverage | Outperform (N/A) |
6.69 (20.24) |
202.54% | Details | |
| 1/4/2019 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/2/2019 | Genocea Biosciences | GNCA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/3/2018 | Tesaro | TSRO | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2018 | Paratek Pharmaceuticals | PRTK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/26/2018 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/19/2018 | Merrimack Pharmaceuticals | MACK | Maintain | Neutral (N/A) |
|
Details | ||
| 9/26/2018 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2018 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/21/2018 | GTX Inc. | GTXI | Downgrade | Neutral (Outperform) |
23.29 (1.20) |
-94.85% | Details | |
| 9/19/2018 | Surface Oncology | SURF | New Coverage | Outperform (N/A) |
10.24 (1.07) |
-89.55% | Details | |
| 8/15/2018 | Mersana | MRSN | Maintain | Outperform (N/A) |
|
Details |
